Click here to close now.


Wearables Authors: Chris Fleck, Anders Wallgren, Liz McMillan, JP Morgenthal, Kevin Benedict

News Feed Item

World Glucose Self-Testing Markets

LONDON, Aug. 4, 2014 /PRNewswire/ -- has added a new market research report:

World Glucose Self-Testing Markets

The worldwide incidence of diabetes is dramatically increasing, and it is estimated that 439 million people will have developed the disease by 2030. As such, the global market for blood glucose self-testing products is undergoing a significant transition driven by the advent of new analytical technologies and new recommendations for tight glucose control for monitoring diabetes. In addition, the proliferation of the middle class within developing nations, particularly China and India, has resulted in both a substantial rise in Type 2 diabetes and the financial means to manage the disease. The purpose of this TriMark Publications report is to provide a comprehensive analysis of the specific segment of the over-the-counter diagnostics sector known as the glucose self-testing market. The term "self-testing" is used to distinguish it from in vitro diagnostics testing for blood glucose in hospitals, commercial labs and doctor's offices, the so-called "professional" component of the glucose testing market. This study reviews the viable technology drivers and assesses the market dynamics of the glucose self-testing market worldwide. This report also looks at the industry challenges and potential threats, and it makes strategic recommendations for boosting market share. Detailed tables and charts with sales forecasts and market share data are also included.

1. Overview 11

1.1 Statement of Report 11

1.2 About This Report 11

1.3 Scope of the Report 12

1.4 Objectives 13

1.5 Methodology 14

1.6 Executive Summary 15


2. Diabetes 18

2.1 Demographics of Diabetes 19

2.1.1 Worldwide Diabetes Incidence 19

2.1.2 Diabetes in the U.S. 23

2.2 Understanding the Metabolic Conditions Underlying and Associated with Diabetes 28

2.2.1 Pre-Diabetes Syndrome 29

2.2.2 Metabolic Syndrome 29

2.2.3 Progression of Diabetes 29

2.2.4 Diabetes and Inflammation 30

2.2.5 Risk Factors and Diabetes 30 Obesity 31 Stress-Induced Hyperglycemia 33

2.2.6 Complications and Co-Morbidities in Diabetes 34 Preventing Complications and Co-Morbidities in Diabetes 38

2.3 Economics of Diabetes 39

2.3.1 Worldwide Costs of Diabetes 40

2.3.2 Costs of Diabetes in the U.S. 40


3. Market Analysis: Size, Growth, Share and Competitors 45

3.1 Worldwide Glucose Testing Market 45

3.2 Global Glucose Self-Testing Market 47

3.2.1 Continuous Glucose Monitoring Markets 50

3.3 U.S. Market 51

3.4 European Market 55

3.5 Asian Market 56

3.5.1 Japanese Market 57

3.5.2 Chinese Market 58

3.5.3 Indian Market 60

3.5.4 Korean Market 61

3.5.5 Southeast Asian Market 61

3.5.6 ROW Markets 62

3.6 Competitive Situation 63

3.6.1 Key Players 63

3.6.2 Analyses of the Current Market Conditions, Competition and Product Mix 63

3.7 Market Drivers and Restraints 66

3.7.1 Market Drivers 66

3.7.2 Market Restraints 68

3.8 Market and Product Trends 69

3.8.1 Market Trends 70

3.8.2 Technology Trends 71

3.9 Strategic Recommendations 72

3.10 Competitive Strategies 74

3.11 Adjacent Markets 75


4. Glucose Diagnostic and Monitoring Recommendations 76

4.1 Diagnosis of Diabetes Mellitus 76

4.2 Tight Glucose Control in Treating Diabetes 79

4.2.1 Tight Glucose Control Lowers Cardiovascular Complications 80

4.3 Recommendations for Glucose Control in Diabetic Patients 80

4.3.1 Recommended Frequency of Blood Glucose Testing 82

4.3.2 Using Blood Glucose Data to Monitor and Modify Patient Therapy 83

4.3.3 Testing in Individuals with Type 2 Diabetes 84

4.3.4 Continuous Glucose Monitoring (CGM) 85

4.3.5 A1c Testing Recommendations 86

4.4 Hypoglycemia and Treatment 86


5. Glucose Self-Testing Technology Platforms and Consumable Products 89

5.1 Types of Glucose Self-Testing Devices 89

5.2 Enzymatic Reactions Used in Glucose Self-Testing Devices 90

5.2.1 Glucose Oxidase (GOX) 90

5.2.2 Glucose Dehydrogenase (GDH) 91 GDH-NAD (Glucose Dehydrogenase-Nicotinamide Adenine Dinucleotide) 91 GDH-FAD (Glucose Dehydrogenase-Flavin Adenine Dinucleotide) 91 GDH-PQQ (Glucose Dehydrogenase-Pyrroloquinoline Quinone) 91

5.2.3 Glucose Hexokinase 92

5.3 Development of Blood Glucose Monitors: A Historical Evaluation 92

5.3.1 First-Generation Blood Glucose Biosensors 92

5.3.2 Second-Generation Blood Glucose Biosensors 92

5.3.3 Third-Generation Blood Glucose Biosensor 93

5.4 Accuracy and Precision in Glucose Meters 93

5.4.1 International Organization for Standardization (ISO) 15197:2013 94

5.4.2 FDA Guidelines for Blood Glucose Testing Systems 95

5.4.3 Determining Clinical Accuracy Using the Error Grid Analysis (EGA) 98

5.4.4 Quality Control Criteria 99

5.4.5 Potential Variables Affecting Glucose Concentrations 99

5.4.6 Calibration Methods 99

5.4.7 Common User Errors 100

5.5 Key Issues for Glucose Self-Testing Devices 100

5.5.1 Important Elements for Glucose Self-Testing 102

5.5.2 Key Features to Aid Specific Patient Populations 103

5.6 Limitations of Existing Glucose Self-Testing Products 104

5.7 Interfering Substances and Conditions 105

5.7.1 Environmental 105

5.7.2 Physiologic 105

5.7.3 Operational 105

5.7.4 Manufacturing Variations 106

5.7.5 Drugs 106

5.7.6 Patient Factors 106 Errors Associated with GDH-PQQ Technology 106

5.8 Potential Areas of Improvement in Blood Glucose Monitor Performance 109

5.8.1 Blood Glucose Reagent Test Strips 109

5.9 Continuous Glucose Monitoring Technology 111

5.9.1 Advantages of Continuous Readings 112

5.9.2 FDA Approval of CGM 112

5.9.3 CGM Functions to Consider 113

5.9.4 New Technologies for CGM 113

5.10 Summary of Technologies being Explored for Non-Invasive Glucose Monitoring 114

5.10.1 GlucoTrack 114

5.10.2 Non-Invasive Glucose Monitoring Technologies in Development 114

5.10.3 Goals of Non-Invasive Testing 115

5.10.4 Non-Invasive Diabetes Screening Test 116

5.11 A1c Monitoring Technology 116

5.12 Fructosamine Test 118

5.13 Related Reagents and Equipment 119

5.13.1 Lancets 119 Types of Lancing Devices 119 Market Size 120

5.13.2 Control Solutions and Calibrators 125

5.13.3 Sharps Devices 125

5.13.4 Needle Destruction Devices 126

5.13.5 Ketone Testing 126

5.14 New Developments in Glucose Self-Testing Systems 127

5.14.1 Voice Operated Glucose Self-Testing Meters 127

5.14.2 Bluetooth-Enabled Glucose Self-Testing Meters 130 MyGlucoHealth Wireless Meter 130 Fora D15b, Fora G31 and Fora D30 Meters 130 OneTouch VerioSync Blood Glucose Monitoring System 130 Telcare BGM 131

5.14.3 Glucose Self-Testing Meters with Computer Connectivity 131

5.14.4 Data Management 131 Log Sheets/Spreadsheets 131 Glucose Self-Testing Software 131 Smart Phone and iPad/iPod Touch Applications 133

5.14.5 Remote Patient Monitoring 135 Infopia Eocene System 137 Health Buddy Systems Monitoring Technologies 137 GlucoCom Glucose Monitoring System 138 Alere's DayLink Monitor 138 Alere HomeLink Receives FDA Approval for Over-the-Counter Use 138

5.14.6 Integrated Testing: Glucose Meter, Test Strips and Lancet 139

5.14.7 Long-Term Glucose Sensing Bio-Implants 139

5.14.8 Glucose Self-Testing Meters that Wirelessly Communicate with Insulin Pumps 140 Medtronic's MiniMed Paradigm Revel 140 MiniMed 530G with Enlite 140 Nova Max Link 140 One Touch Ultra Link 140 One Touch Ping 140 Accu-Chek Combo System 141


6. Glucose Self-Testing Meters on the Market: Description of Test Meters 142

6.1 Blood Glucose Self-Testing Meters and Strips 142

6.1.1 LifeScan, Inc. 145

6.1.2 Roche Diagnostics Corporation 148

6.1.3 Bayer 149

6.1.4 Abbott (MediSense) 151

6.1.5 Agamatrix, Inc. 153

6.1.6 ARKRAY, Inc. 154

6.1.7 Bionime Corporation 156

6.1.8 BioSense Medical Devices 157

6.1.9 CVS/Pharmacy 158

6.1.10 Diabetic Supply of Suncoast 158

6.1.11 Entra Health Systems 158

6.1.12 Fifty50 Pharmacy 158

6.1.13 Fora Care 159

6.1.14 Genesis Health Technologies 160

6.1.15 GlucoCom 160

6.1.16 Infopia 160

6.1.17 Nipro Diagnostics, Inc. 161

6.1.18 Nova Biomedical 162

6.1.19 Oak Tree International Holdings, Inc. 162

6.1.20 Omnis Health 163

6.1.21 Phylosis 163

6.1.22 Prodigy Diabetes Care, LLC (an affiliate of Diagnostic Devices, Inc.) 163

6.1.23 Sanofi 164

6.1.24 Target 164

6.1.25 Telcare 164

6.1.26 Tyson Biomedical 165

6.1.27 US Diagnostics 165

6.1.28 Walgreens 166

6.1.29 Walmart 166

6.1.30 77 Elektronika Kft. 166

6.1.31 A. Menarini Diagnostics 167

6.1.32 All Medicus 167

6.1.33 i-SENS 167

6.1.34 Apex Biotechnology Corp. 168

6.1.35 Glucoplus, Inc. 168

6.1.36 Polymer Technology Systems 168

6.1.37 Smiths Medical MD, Inc. 168

6.1.38 TaiDoc Technology Corp. 168

6.1.39 IN4 Technology Corporation 168

6.1.40 ACON Laboratories 169

6.1.41 Pepex Biomedical 169

6.1.42 HMD BioMedical 170

6.1.43 BTNX, Inc. 170

6.1.44 Shasta Technologies and Decision Diagnostics Corporation 170

6.2 Continuous and Non-Invasive Glucose Patient Monitoring Systems 170

6.2.1 Medtronic's Continuous Glucose Monitoring Systems (CGMS) 172

6.2.2 DexCom, Inc. G4 Platinum Continuous Glucose Monitoring System 174

6.2.3 FreeStyle Navigator—Abbott's Continuous Glucose Monitor System 176

6.2.4 GlucoDay S Continuous Glucose Monitor 177

6.2.5 Minimally-Invasive Continuous Glucose Monitors in Development 177 GlySens, Inc. 177 Senseonics (formerly Sensors for Medicine and Science) 177 Ultradian 178 GluMetrics, Inc. 178

6.3 Non-Invasive Glucose Patient Monitoring Systems in Development 178

6.3.1 Cygnus GlucoWatch Biographer 179

6.3.2 AiMedics 179

6.3.3 BioTex, Inc. 180

6.3.4 Echo Therapeutics, Inc. 180

6.3.5 EyeSense GmbH 181

6.3.6 Integrity Applications Ltd. 181

6.3.7 LighTouch Medical, Inc. 182

6.3.8 OrSense Ltd. 182

6.3.9 VeraLight, Inc. 182

6.3.10 Xhale, Inc. 183

6.3.11 Lein Applied Diagnostics 183

6.4 A1c Self-Testing 183

6.4.1 A1CNow SELFCHECK 183

6.4.2 DTI Laboratories 184

6.4.3 ReliOn A1c Test 184

6.5 New Product Launches 184

6.5.1 OneTouch VerioSync Blood Glucose Monitoring System 184

6.5.2 Medtronic's MiniMed 530G with Enlite Sensor Technology, the First Artificial Pancreas Device

System 185

6.5.3 Contour Next Link Meter Approved for Use with Medtronic's New MiniMed 530G with Enlite Insulin Pump System 185

6.5.4 Abbott Receives CE Mark for FreeStyle Optium Neo Blood Glucose and Ketone Monitoring

System 185

6.5.5 LabStyle Innovations' Dario Diabetes Management System 185

6.5.6 BlueStar by WellDoc 186

6.5.7 FDA Approves Bayer's Contour Next EZ 186

6.5.8 Glooko Received its Second 510(k) Clearance for Glucose Monitoring Logbook App 186

6.5.9 Sanofi-Aventis's iBGStar 187

6.5.10 iHealth Glucose Meter Device 187

6.5.11 MyGlucoHealth Diabetes 187

6.5.12 gDrive 188

6.5.13 Enlite Sensor 188

6.5.14 Abbott's FreeStyle InsuLinx 188

6.5.15 Roche Diagnostics Launches Accu-Chek Mobile 188

6.5.16 Medtronic Announces Mac Compatibility for CareLink Personal Therapy Management Software for Diabetes 189

6.5.17 Telcare Receives FDA Clearance for its Telcare BGM 3G Blood Glucose Meter 189

6.5.18 OneTouch SelectSimple 189

6.5.19 Shasta GenStrips 189

6.6 Blood Glucose Meters, CGMs, and Data Management Software in Development 189

6.6.1 Abbott's Flash Glucose Monitoring System 189

6.6.2 Google Announces Plan to Create Contact Lens Glucose Sensors 190

6.6.3 Socrates Health Solutions' Companion Blood Glucose Monitor 190

6.6.4 DexCom and Johnson and Johnson's Animas Working to Develop an Artificial Pancreas 190

6.6.5 Medtronic Enrolling Patients into Trial Testing Third-Generation, Fully-Automated Artificial

Pancreas 190

6.6.6 Boston University's Bionic Pancreas Project 190

6.7 Recent Industry Activity 190

6.7.1 Roche Diagnostics Corp. Cutting Jobs in Diabetes Division 190

6.7.2 AgaMatrix and Sanofi-Aventis Enter Global Diabetes Partnership 190

6.7.3 LifeScan, Inc. Terminates Exclusive Supply Agreement with Medtronic MiniMed 191

6.7.4 Kroger Selects WaveSense Diabetes Testing Products 191

6.7.5 Medtronic and Bayer Healthcare Expand International Alliance 191

6.7.6 PositiveID Corporation and IDEAL LIFE Partner to Bring iglucose to Market for Wireless Diabetes Management 191

6.7.7 Roche Diagnostics U.S. and DexCom, Inc. Announce Research and Development Agreement 191

6.7.8 BD and JDRF Collaborating on a Device Using a Single Infusion Catheter for Both CGM and

Pump 192

6.7.9 Court Sides with Decision Diagnostics in Patent Infringement Case 192

6.8 M&A Activity 192

6.8.1 Home Diagnostics, Inc. and Nipro Diabetes Systems, Inc. Merge to become Nipro

Diagnostics, Inc. 192

6.8.2 Medtronic, Inc. (MDT) Acquires New Diabetes Technology from PreciSense AS 192

6.8.3 Geonostics Acquires FlexSite's Consumer Diabetes Tests 193

6.8.4 Additional M&A 193

6.8.5 Important Deals in BGM Market 194


7. Business Trends in the Industry 195

7.1 Wholesale Distribution Overview 195

7.2 Factors Affecting OTC Medical Product Distribution 197

7.3 Drugstores Critical to the Diabetic Care Category 198

7.4 Drivers of OTC and Self-Testing Markets 199

7.4.1 Brand Loyalty 199

7.5 Cost Elements of Glucose Self-Testing 199

7.6 Important Elements of OTC Testing 200

7.7 Growth of Home Care and Self-Testing 200

7.8 Blood Glucose Self-Testing Insurance Coverage and Reimbursement 200

7.8.1 American OTC Testing and Self-Testing Reimbursement 200

7.8.2 European Reimbursement 203

7.8.3 Reimbursement Challenges 203

7.8.4 New Medicare Part B 204

7.9 Government Regulation of Medical Devices 204

7.9.1 U.S. Regulations 204

7.9.2 E.U. Regulations 207

7.9.3 U.K. Regulations 212

7.10 Clinical Laboratory Improvement Act (CLIA) 213

7.11 FDA Labeling Requirements 215

7.12 Legal Liability for Glucose Meters 217

7.13 FDA's Artificial Pancreas Guidance Document 217


8. Technology Trends 218

8.1 Improving Today's Over-the-Counter (OTC) Blood Glucose Meters 218

8.2 Biosensor Technology 219

8.3 Artificial Pancreas 221

8.4 Fructosamine Test 222

8.5 Telemedicine 223

8.5.1 Remote Patient Monitoring 225 Infopia Eocene System 229 Health Buddy Systems Monitoring Technologies 229 GlucoCom Glucose Monitoring System 229 Alere's DayLink Monitor 230 Alere HomeLink Receives FDA Approval for Over-the-Counter Use 230

8.6 Non-Traditional Methods for Sample Collection 230

8.7 Data Management 231

8.7.1 Medical Device Radiocommunications Service (MedRadio) 231

8.7.2 FDA Required Software Verification 231


9. OTC Testing: Critical Issues 232

9.1 Moderators of Growth for OTC Testing 232

9.2 Attitudes of Critical Care Nurses and Physicians 232

9.3 Personnel Impact for OTC Testing 233

9.4 Data Management Issues 233


10. Current Issues for OTC and Diagnostic Self-Testing 234

10.1 New Markets for OTC and Diagnostic Self-Testing 234

10.2 Utility of OTC and Self-Testing 235

10.3 Generational Drivers of Home Testing 236

10.4 Move Away from Central Laboratories 237

10.5 Healthcare Cost Controls 238

10.6 Mergers of Diagnostic Companies 238

10.7 Home Healthcare Trends 238

10.8 Home Healthcare Providers versus Mass Market Retailers 238

10.9 Demographic Merchandising 239

10.10 Marketing Strategies 239

10.11 Third-Party Pharmacy Networks 240

10.12 Which Customer Segments Purchase Home Healthcare? Which Products Fit Their Needs? 240

10.13 Future of Patient Self-Testing 242


11. SWOT Analysis 243

11.1 Roche 243

11.2 LifeScan 243


12. Company Profiles 246

12.1 A. Menarini Diagnostics 246

12.2 Abbott Laboratories 246

12.3 ACON Laboratories 250

12.4 AgaMatrix 250

12.5 Allmedicus Co., Ltd. 250

12.6 Apex Biotechnology Corporation 250

12.7 ARKRAY USA, Inc. 250

12.8 Bayer 251

12.9 B. Braun Melsungen 252

12.10 Bionime 253

12.11 Cambridge Sensors 253

12.12 DexCom 253

12.13 Diagnostic Devices/Prodigy Diabetes Care 255

12.14 Echo Therapeutics, Inc. 255

12.15 Entra Health Systems 256

12.16 Fora Care 256

12.17 FIFTY50 Medical, Inc. 256

12.18 Genesis Health Technologies 256

12.19 GlucoPlus 257

12.20 GlySens, Inc. 257

12.21 Hainice Medical 257

12.22 Home Diagnostics 257

12.23 Infopia 258

12.24 IN4 Technology 258

12.25 i-Sens 258

12.26 Johnson & Johnson 258

12.27 LabStyle Innovations Corporation 259

12.28 Medtronic 259

12.29 Nipro Corporation 259

12.30 Nova Biomedical 260

12.31 OrSense Ltd. 260

12.32 Prodigy Diabetes Care, LLC (formerly Diagnostic Devices, Inc.) 260

12.33 Roche 261

12.34 77 Elektronika Kft. 262

12.35 Smiths Group 262

12.36 TaiDoc Technology 262

12.37 Telcare 263

12.38 US Diagnostics 263

12.39 VeraLight 263






Figure 2.1: Worldwide Diabetes Cases, 2013 and 2035 19

Figure 2.2: Worldwide Prevalence of Diabetes (%) in Adults (20-79 Years), 2013 20

Figure 2.3: Annual Number of New Cases of Diagnosed Diabetes Among U.S. Adults Aged 18-79 Years,

1980-2011 23

Figure 2.4: New Cases of Diabetes Diagnosed in the U.S. Adult Population by Age, 2010 24

Figure 2.5: Prevalence of Diabetes by Age in the U.S., 2010 24

Figure 2.6: Diagnosed Diabetes by Age in the U.S., 2013 25

Figure 2.7: Number of Deaths from Diabetes by Age in the U.S., 2010 27

Figure 2.8: Number of Diabetes Deaths by Race and Sex in the U.S., 2010 27

Figure 2.9: Maintenance of Normal Blood Sugar Levels 28

Figure 2.10: Prevalence of Self-Reported Obesity (BMI ?30) Among U.S. Adults, 2012 32

Figure 2.11: Prevalence of Obesity Among Adults in the U.S., 2009-2010 32

Figure 2.12: Trends in Obesity Among Children and Adolescents in the U.S., 1988-2010 33

Figure 2.13: Age-Adjusted Percentage of People with Diabetes Aged 35 Years or Older Reporting Heart Disease or Stroke, by Sex, in the U.S., 1997-2011 35

Figure 2.14: Percentage of Adults with Diagnosed Diabetes Reporting Any Mobility Limitation, by Age, in the U.S., 1997-2011 37

Figure 2.15: Number (in Millions) of Adults Aged 18 Years or Older with Diagnosed Diabetes Reporting Visual Impairment in the U.S., 1997-2011 38

Figure 2.16: Mean Diabetes Healthcare-Related Expenditures Per Adult (20-79 Years) with Diabetes (U.S. Dollars), 2013 40

Figure 2.17: How Diabetes Dollars are Spent in the U.S., 2012 42

Figure 3.1: Geographic Segments of the Worldwide Glucose Self-Testing Market, 2012 and 2018 48

Figure 3.2: Worldwide Glucose Self-Testing Market by Region, 2018 48

Figure 3.3: Worldwide Glucose Self-Testing Market Segments, 2013 49

Figure 4.1: Approach to Management of Hypoglycemia 82

Figure 4.2: Glycemic Status—Ranges and Health Implications 88

Figure 5.1: EGA Zones of Clinical Accuracy 98

Figure 5.2: Single-Day Continuous Blood Glucose Data 105

Figure 5.3: Factors that may Adversely Affect Glucose Testing 106

Figure 5.4: Personal Lancet Unit Sales Market Share by Geographic Region, 2013 122

Figure 6.1: Medtronic's Threshold Suspend Feature 174





Table 2.1: Regional Estimates of the Number of Diabetes (20-79 Years) in Millions, 2013 and 2035 20

Table 2.2: Countries with the Largest Numbers of Diabetics, 2013 21

Table 2.3: Countries with the Largest Estimated Numbers of Diabetics, 2035 21

Table 2.4: Worldwide Undiagnosed Diabetes in Adults (20-79 Years) by Region and Income Group, 2013 22

Table 2.5: Countries with the Largest Number of Deaths Attributable to Diabetes, 2013 22

Table 2.6: U.S. Population of Diagnosed Diabetics Aged 20-79 Years, 2013 24

Table 2.7: Percentage of U.S. Adults with Diagnosed Diabetes by State, 2010 25

Table 2.8: Ten Leading Diagnoses for Co-Morbid Chronic Diseases in the U.S. 34

Table 2.9: Odds Ratio of Progression to Complications Associated with Type 2 Diabetes 36

Table 2.10: Prevalence of Complications Among Patients with Diabetes 36

Table 2.11: Novel Risk Factors and Possible Mechanisms of the Excess Risk of Coronary Heart Disease in Type 2 Diabetes Mellitus 37

Table 2.12: Major Causes of End-Stage Renal Disease 37

Table 2.13: Clinical Recommendations for Adults with Diabetes 39

Table 2.14: Laboratory Assessment of Diabetic Vascular Disease 39

Table 2.15: Average Years Gained Free of Diabetes-Related Disease with Intensive Management 39

Table 2.16: Cost of Diagnosed Diabetes in the U.S., 2012 41

Table 2.17: Annual Cost of Care of United Healthcare Adult Members with Diabetes, 2009 43

Table 2.18: Healthcare Utilization by Diabetic Patients, 2012 43

Table 3.1: Total Global Unit Demand for Glucose Testing Reagent Strips, 2012-2018 46

Table 3.2: Global Dollar Sales of Glucose Testing Reagent Strips, 2012-2018 47

Table 3.3: Worldwide Glucose Self-Testing Market Sales (Meters, Strips and Lancets), 2012-2018 47

Table 3.4: World Market Share of Glucose Self-Testing Marketers, 2013 49

Table 3.5: Global Revenues for Continuous Glucose Monitoring Systems, 2012-2018 50

Table 3.6: Market for Glucose Self-Testing in the U.S. (Includes Meters, Strips and Lancets), 2012-2018 51

Table 3.7: Market Share of U.S. Blood Glucose Self-Testing, 2013 52

Table 3.8: U.S. OTC Glucose Self-Testing Market Repeat Retail Replacement Sales Percentages 53

Table 3.9: OTC Blood Glucose Instrument Reagents by Manufacturer Retail 53

Table 3.10: Demographic Characteristics Glucose Self-Testing Kit Buyers 54

Table 3.11: Top Brand Preferences for Glucose Self-Testing Kits 54

Table 3.12: Instances when Patients Prefer Professional's Glucose Testing 54

Table 3.13: Advantages of a Glucose Self-Testing Kit 55

Table 3.14: Disadvantages of Using a Glucose Self-Testing Kit 55

Table 3.15: Popular Shopping Destinations for Buying or Seeking Information on Glucose Self-Testing

Kits 55

Table 3.16: Customer Priorities—Glucose Meter Self-Testing Market, 2001, 2006 and 2013 55

Table 3.17: European Market for Glucose Self-Testing (Includes Meters, Strips and Lancets), 2012-2018 56

Table 3.18: Asian Market for Glucose Self-Testing (Includes Meters, Strips and Lancets), 2012-2018 57

Table 3.19: Japanese Market for Glucose Self-Testing (Includes Meters, Strips and Lancets), 2012-2018 58

Table 3.20: Chinese Market for Glucose Self-Testing (Includes Meters, Strips and Lancets), 2012-2018 59

Table 3.21: Southeast Asian Market for Glucose Self-Testing (Includes Meters, Strips and Lancets),

2012-2018 62

Table 3.22: Southeast Asian Market for Glucose Self-Testing by Country (Includes Meters, Strips and Lancets), 2013 62

Table 3.23: ROW Market for Glucose Self-Testing (Includes Meters, Strips and Lancets), 2012-2018 62

Table 3.24: Key Market Drivers for Glucose Self-Testing 67

Table 3.25: Market Drivers for Continuous Glucose Monitoring 67

Table 3.26: Key Market Restraints for Glucose Self-Testing 68

Table 3.27: Market Restraints for Continuous Glucose Monitoring 69

Table 4.1: Criteria for the Diagnosis of Diabetes 76

Table 4.2: Categories of Increased Risk for Diabetes (Pre-Diabetes) 76

Table 4.3: Normal Glucose Values—Fasting State 77

Table 4.4: Criteria for Testing for Diabetes in Asymptomatic Adults 77

Table 4.5: Criteria for Type 2 Diabetes in Asymptomatic Children 78

Table 4.6: Screening for and Diagnosis of Gestational Diabetes Mellitus (GDM) 79

Table 4.7: Glycemic Recommendations for Non-Pregnant Adults with Diabetes 81

Table 4.8: Glycemic Recommendations for Women with Gestational Diabetes 81

Table 4.9: Glycemic Recommendations for Pregnant Women with Pre-Existing Diabetes 81

Table 4.10: Plasma Blood Glucose and A1c Goals for Type 1 Diabetes by Age-Group 81

Table 4.11: Glucose Monitoring Recommendations 83

Table 4.12: Key Issues for SMBG in Insulin-Independent Type 2 Diabetics 84

Table 4.13: A1c Testing Recommendations 86

Table 4.14: Correlation of A1c with Mean Blood Glucose 86

Table 5.1: Analytic Performance Criteria for Glucose Meters 94

Table 5.2: Potential Variables Affecting Glucose Concentrations 99

Table 5.3: Common User Errors Made while Self-Testing for Blood Glucose 100

Table 5.4: Key Features Considered for Glucose Self-Testing Devices 103

Table 5.5: Key Features Considered for Reagent Test Strips 103

Table 5.6: Compatibility of Various Blood Glucose Meters with Icodextrin PD Solution 107

Table 5.7: Ten Factors Needed to Improve the Performance of Blood Glucose Monitors 109

Table 5.8: Key Features Considered for Reagent Test Strips 110

Table 5.9: Relationship of A1c to Average Whole Blood and Plasma Glucose Levels 117

Table 5.10: Unit Sales of Homecare Lancets in the U.S., 2012-2017 121

Table 5.11: Unit Sales of Homecare Lancets in the E.U., 2012-2017 121

Table 5.12: Dollar Sales of Homecare Lancets in the U.S., 2012-2017 121

Table 5.13: Dollar Sales of Homecare Lancets in the E.U., 2012-2017 121

Table 5.14: Unit Sales of Homecare Glu



Read the full report:

World Glucose Self-Testing Markets

For more information:

Sarah Smith

Research Advisor at

Email: [email protected]

Tel: +44 208 816 85 48



SOURCE ReportBuyer

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

@ThingsExpo Stories
Container technology is shaping the future of DevOps and it’s also changing the way organizations think about application development. With the rise of mobile applications in the enterprise, businesses are abandoning year-long development cycles and embracing technologies that enable rapid development and continuous deployment of apps. In his session at DevOps Summit, Kurt Collins, Developer Evangelist at, examined how Docker has evolved into a highly effective tool for application delivery by allowing increasingly popular Mobile Backend-as-a-Service (mBaaS) platforms to quickly crea...
Discussions of cloud computing have evolved in recent years from a focus on specific types of cloud, to a world of hybrid cloud, and to a world dominated by the APIs that make today's multi-cloud environments and hybrid clouds possible. In this Power Panel at 17th Cloud Expo, moderated by Conference Chair Roger Strukhoff, panelists addressed the importance of customers being able to use the specific technologies they need, through environments and ecosystems that expose their APIs to make true change and transformation possible.
With major technology companies and startups seriously embracing IoT strategies, now is the perfect time to attend @ThingsExpo 2016 in New York and Silicon Valley. Learn what is going on, contribute to the discussions, and ensure that your enterprise is as "IoT-Ready" as it can be! Internet of @ThingsExpo, taking place Nov 3-5, 2015, at the Santa Clara Convention Center in Santa Clara, CA, is co-located with 17th Cloud Expo and will feature technical sessions from a rock star conference faculty and the leading industry players in the world. The Internet of Things (IoT) is the most profound cha...
Internet of @ThingsExpo, taking place June 7-9, 2016 at Javits Center, New York City and Nov 1-3, 2016, at the Santa Clara Convention Center in Santa Clara, CA, is co-located with the 18th International @CloudExpo and will feature technical sessions from a rock star conference faculty and the leading industry players in the world and ThingsExpo New York Call for Papers is now open.
The cloud. Like a comic book superhero, there seems to be no problem it can’t fix or cost it can’t slash. Yet making the transition is not always easy and production environments are still largely on premise. Taking some practical and sensible steps to reduce risk can also help provide a basis for a successful cloud transition. A plethora of surveys from the likes of IDG and Gartner show that more than 70 percent of enterprises have deployed at least one or more cloud application or workload. Yet a closer inspection at the data reveals less than half of these cloud projects involve production...
Growth hacking is common for startups to make unheard-of progress in building their business. Career Hacks can help Geek Girls and those who support them (yes, that's you too, Dad!) to excel in this typically male-dominated world. Get ready to learn the facts: Is there a bias against women in the tech / developer communities? Why are women 50% of the workforce, but hold only 24% of the STEM or IT positions? Some beginnings of what to do about it! In her Day 2 Keynote at 17th Cloud Expo, Sandy Carter, IBM General Manager Cloud Ecosystem and Developers, and a Social Business Evangelist, wil...
Cloud computing delivers on-demand resources that provide businesses with flexibility and cost-savings. The challenge in moving workloads to the cloud has been the cost and complexity of ensuring the initial and ongoing security and regulatory (PCI, HIPAA, FFIEC) compliance across private and public clouds. Manual security compliance is slow, prone to human error, and represents over 50% of the cost of managing cloud applications. Determining how to automate cloud security compliance is critical to maintaining positive ROI. Raxak Protect is an automated security compliance SaaS platform and ma...
In his keynote at @ThingsExpo, Chris Matthieu, Director of IoT Engineering at Citrix and co-founder and CTO of Octoblu, focused on building an IoT platform and company. He provided a behind-the-scenes look at Octoblu’s platform, business, and pivots along the way (including the Citrix acquisition of Octoblu).
Today air travel is a minefield of delays, hassles and customer disappointment. Airlines struggle to revitalize the experience. GE and M2Mi will demonstrate practical examples of how IoT solutions are helping airlines bring back personalization, reduce trip time and improve reliability. In their session at @ThingsExpo, Shyam Varan Nath, Principal Architect with GE, and Dr. Sarah Cooper, M2Mi’s VP Business Development and Engineering, explored the IoT cloud-based platform technologies driving this change including privacy controls, data transparency and integration of real time context with p...
There are over 120 breakout sessions in all, with Keynotes, General Sessions, and Power Panels adding to three days of incredibly rich presentations and content. Join @ThingsExpo conference chair Roger Strukhoff (@IoT2040), June 7-9, 2016 in New York City, for three days of intense 'Internet of Things' discussion and focus, including Big Data's indespensable role in IoT, Smart Grids and Industrial Internet of Things, Wearables and Consumer IoT, as well as (new) IoT's use in Vertical Markets.
The Internet of Things (IoT) is growing rapidly by extending current technologies, products and networks. By 2020, Cisco estimates there will be 50 billion connected devices. Gartner has forecast revenues of over $300 billion, just to IoT suppliers. Now is the time to figure out how you’ll make money – not just create innovative products. With hundreds of new products and companies jumping into the IoT fray every month, there’s no shortage of innovation. Despite this, McKinsey/VisionMobile data shows "less than 10 percent of IoT developers are making enough to support a reasonably sized team....
We all know that data growth is exploding and storage budgets are shrinking. Instead of showing you charts on about how much data there is, in his General Session at 17th Cloud Expo, Scott Cleland, Senior Director of Product Marketing at HGST, showed how to capture all of your data in one place. After you have your data under control, you can then analyze it in one place, saving time and resources.
Just over a week ago I received a long and loud sustained applause for a presentation I delivered at this year’s Cloud Expo in Santa Clara. I was extremely pleased with the turnout and had some very good conversations with many of the attendees. Over the next few days I had many more meaningful conversations and was not only happy with the results but also learned a few new things. Here is everything I learned in those three days distilled into three short points.
As organizations realize the scope of the Internet of Things, gaining key insights from Big Data, through the use of advanced analytics, becomes crucial. However, IoT also creates the need for petabyte scale storage of data from millions of devices. A new type of Storage is required which seamlessly integrates robust data analytics with massive scale. These storage systems will act as “smart systems” provide in-place analytics that speed discovery and enable businesses to quickly derive meaningful and actionable insights. In his session at @ThingsExpo, Paul Turner, Chief Marketing Officer at...
DevOps is about increasing efficiency, but nothing is more inefficient than building the same application twice. However, this is a routine occurrence with enterprise applications that need both a rich desktop web interface and strong mobile support. With recent technological advances from Isomorphic Software and others, rich desktop and tuned mobile experiences can now be created with a single codebase – without compromising functionality, performance or usability. In his session at DevOps Summit, Charles Kendrick, CTO and Chief Architect at Isomorphic Software, demonstrated examples of com...
In his General Session at 17th Cloud Expo, Bruce Swann, Senior Product Marketing Manager for Adobe Campaign, explored the key ingredients of cross-channel marketing in a digital world. Learn how the Adobe Marketing Cloud can help marketers embrace opportunities for personalized, relevant and real-time customer engagement across offline (direct mail, point of sale, call center) and digital (email, website, SMS, mobile apps, social networks, connected objects).
Two weeks ago (November 3-5), I attended the Cloud Expo Silicon Valley as a speaker, where I presented on the security and privacy due diligence requirements for cloud solutions. Cloud security is a topical issue for every CIO, CISO, and technology buyer. Decision-makers are always looking for insights on how to mitigate the security risks of implementing and using cloud solutions. Based on the presentation topics covered at the conference, as well as the general discussions heard between sessions, I wanted to share some of my observations on emerging trends. As cyber security serves as a fou...
The Internet of Everything is re-shaping technology trends–moving away from “request/response” architecture to an “always-on” Streaming Web where data is in constant motion and secure, reliable communication is an absolute necessity. As more and more THINGS go online, the challenges that developers will need to address will only increase exponentially. In his session at @ThingsExpo, Todd Greene, Founder & CEO of PubNub, exploreed the current state of IoT connectivity and review key trends and technology requirements that will drive the Internet of Things from hype to reality.
Continuous processes around the development and deployment of applications are both impacted by -- and a benefit to -- the Internet of Things trend. To help better understand the relationship between DevOps and a plethora of new end-devices and data please welcome Gary Gruver, consultant, author and a former IT executive who has led many large-scale IT transformation projects, and John Jeremiah, Technology Evangelist at Hewlett Packard Enterprise (HPE), on Twitter at @j_jeremiah. The discussion is moderated by me, Dana Gardner, Principal Analyst at Interarbor Solutions.
Too often with compelling new technologies market participants become overly enamored with that attractiveness of the technology and neglect underlying business drivers. This tendency, what some call the “newest shiny object syndrome” is understandable given that virtually all of us are heavily engaged in technology. But it is also mistaken. Without concrete business cases driving its deployment, IoT, like many other technologies before it, will fade into obscurity.